Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133796 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Herceptin in Patients With Breast Cancer
A Phase 2 study, sponsored by Mothaffar Rimawi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00133796: Clinical Trial Phase 2 study, sponsored by Mothaffar Rimawi.
NCT00133796 is a Phase 2 study that was terminated before completion, run by Mothaffar Rimawi. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00133796, a Phase 2 study, was terminated before completion, sponsored by Mothaffar Rimawi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin, together with chemotherapy, is in treating advanced breast cancer.
Interventions
- DRUG Herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-10 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00133796
The ClinicalTrials.gov registry entry for NCT00133796 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mothaffar Rimawi, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Herceptin is the first listed.
NCT00133796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00133796 about?
NCT00133796 is a clinical study titled "Neoadjuvant Herceptin in Patients With Breast Cancer". The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin, together with chemotherapy, is in treating advanced breast cancer.
What is the current status of trial NCT00133796?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-10. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00133796?
The interventions under investigation include: Herceptin (DRUG).
Who is sponsoring clinical trial NCT00133796?
This trial is sponsored by Mothaffar Rimawi, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.